Современные возможности коррекции одышки у больных хронической обструктивной болезнью легких
https://doi.org/10.18093/0869-0189-2013-0-6-79-84
Аннотация
Современные возможности коррекции одышки у больных хронической обструктивной болезнью легких.
Об авторе
Е. И. ШмелевРоссия
д. м. н., профессор, зав. отделом пульмонологии
107564, Москва, Яузская аллея, 2. Тел.: (499) 785-90-08.
Список литературы
1. Al-Shair K., Mullerova H., Locantore N.W. et al. Fatigue significantly associated with COPD exacerbations: data from the ECLIPSE study. Am. J. Respir. Crit. Care Med. 2011; 183: A3974.
2. Global strategy for diagnosis, management, and prevention of COPD. February 2013.
3. Чучалин А.Г. (ред.). Руководство по респираторной медицине. М.: ГЭОТАР, 2007; т. 1–2.
4. De Troyer A., Brunko E., Leduc D., Jammes Y. Reflex inhibition of canine inspiratory intercostals by diaphragmatic tension receptors. J. Physiol. (Lond.) 1999; 514 (1): 255–263.
5. Similowski T., Yan S., Gauthier A.P. et al. Contractile properties of the human diaphragm during chronic hyperinflation. N. Engl. J. Med. 1991; 325: 917–923.
6. Tashkin D.P. The role of small airway inflammation in asthma. Allergy Asthma Proc. 2002; 23 (4): 233–242.
7. Hamid Q.A., Mak J.C., Sheppard M.N. et al. Localization of beta-2-adrenoceptor messenger RNA in human and rat lung using in situ hybridization: correlation with receptor autoradiography. Eur. J. Pharmacol. 1991; 206 (2): 133–138.
8. Adcock I.M., Gilbey T., Gelder C.M. et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am. J. Respir. Crit. Care Med. 1996; 154 (3, Pt 1): 771–782.
9. Lipworth B.J. Targets for inhaled treatment. Respir. Med. 2000; 94 (Suppl. D): S13–S16.
10. Tulic M.K., Christodoulopoulos P., Hamid Q. Small airway inflammation in asthma. Respir. Res. 2001; 2 (6): 333–339.
11. Di Marco F., Milic-Emili J., Boveri B. et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur. Respir. J. 2003; 21: 86–94.
12. Acerbi D., Brambilla G., Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology. Pulm. Pharmacol. Ther. 2007; 20 (3): 290–303.
13. Criee C.P., Meyer T., Petro W. et al. In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single-dose capsule inhaler. J. Aerosol. Med. 2006; 19 (4): 466–472.
14. Meyer T., Brand P., Ehlich H. et al. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J. Aerosol. Med. 2004; 17 (1): 43–49.
15. Brand P., Meyer T., Weuthen T. et al. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J. Clin. Pharmacol. 2007; 47 (10): 1335–1341.
16. Haussermann S., Acerbi D., Brand P. et al. Lung deposition of formoterol HFA (Atimos / Forair) in healthy volunteers, asthmatic and COPD patients. J. Aerosol. Med. 2007; 20 (3): 331–341.
17. Terzano C., Petroianni A., Conti V. et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir. Med. 2008; 102 (12): 1701–1707.
18. Tzani P., Crisafulli E., Nicolini G. et al. Effects of beclomethasone / formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 503–509.
Рецензия
Для цитирования:
Шмелев Е.И. Современные возможности коррекции одышки у больных хронической обструктивной болезнью легких. Пульмонология. 2013;(6):79-84. https://doi.org/10.18093/0869-0189-2013-0-6-79-84
For citation:
Shmelev E.I. Current opportunities to improve dyspnea in patients with chronic obstructive pulmonary disease. PULMONOLOGIYA. 2013;(6):79-84. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-6-79-84